ClinicalTrials.gg
CompletedNCT00540787Updated Feb 28, 2025

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

A Phase 4 interventional study of Radiofrequency ablation, antiarrhythmic drugs and Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs in Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Aug 2003, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.

Enrollment
35th of 58
112 · median 149
Started
2003
the only one that year
Phase 4
10 of 71
none open now
Registered
5th of 71
by date

Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 35th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 4, and was the 5th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Atrial Fibrillation by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.

03

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Paroxysmal atrial fibrillation for at least 6 months with at least 2 symptomatic episodes (patient history) during the previous month
  • Atrial fibrillation (patient history or echocardiogram documented) resistant to at least one antiarrhythmic drug of Class I or III
  • Documentation of at least one episode of atrial fibrillation on 12-lead echocardiogram or Holter Monitor

Exclusion criteria

Exclusion Criteria:

  • to more than 2 antiarrhythmic drugs of different classes, or to oral anticoagulants
  • History of any previous ablation for atrial fibrillation
  • Intracardiac thrombus
  • Atrial fibrillation due to reversible cause
  • Pregnancy
  • Contraindication to stopping oral anticoagulation (for example as a result of a mechanical cardiac valve)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Active comparator
    Drug Treatment

    Device: Radiofrequency ablation, antiarrhythmic drugs · Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs

  • Active comparator
    ThermoCool Radiofrequency Catheter

    Radiofrequency catheter used.

    Device: Radiofrequency ablation, antiarrhythmic drugs · Device: ThermoCool Radiofrequency Catheter

Interventions

  • DeviceRadiofrequency ablation, antiarrhythmic drugs

    Patients receive either treatment.

  • DrugAmiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs

    Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.

  • DeviceThermoCool Radiofrequency Catheter

    Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.

06

What researchers measure

Primary outcomes

  1. Recurrence of Atrial Fibrillation

    To compare the incidence of recurrence of Atrial Fibrillation in the two groups over a follow-up period of one year.

    Time frame: One year

Secondary outcomes

  1. Efficacy of ablation and drug treatment

    Evaluation of: * the functional state of the 2 groups of patients in terms of quality of life * the efficacy of the subgroup receiving amiodarone as compared to curative ablation * the incidence of secondary effects of both approaches * the rate of withdrawal from oral anticoagulation at 1 year after randomization * the effect of ablation for maintenance of sinus rhythm with previously ineffective drugs in case of failure of ablation strategy (after cross-over to medical treatment) * the assessment of Atrial fibrillation burden in both groups (using patient diaries and Holter Monitors)

    Time frame: One year

07

Study locations

6 sites
  • University of Alabama, Birmingham
    Birmingham, Alabama 35294, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mid-Ohio Cardiology
    Columbus, Ohio 43214, United States
  • Hôpital Haut Lèvêque
    Pessac, Paris, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Hopital Cantonal de Geneve
    Geneva, 12111, Switzerland
08

References and documents

Publications

  • Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clementy J, Haissaguerre M. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008 Dec 9;118(24):2498-505. doi: 10.1161/CIRCULATIONAHA.108.772582. Epub 2008 Nov 24. PubMed 19029470 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2003 to primary completion in Jun 2006, 34 months.

Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 8, 2007
StartActual
Aug 1, 2003
Primary completionActual
Jun 1, 2006
CompletionActual
Jun 1, 2006
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00540787
Responsible party
Sponsor
First posted
Oct 8, 2007
Start date
Aug 1, 2003
Primary completion
Jun 1, 2006
Completion
Jun 1, 2006
Last update
Feb 28, 2025

Study contacts

Pierre Jais, MD
principal investigator · Hôpital Haut Lèvêque
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion